References
- 1
Göschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H.
Botulinum A toxin therapy: neutralizing and non-neutralizing antibodies - therapeutic
consequences.
Exp Neurol.
1997;
147
96-102
- 2
Greene P, Fahn S, Diamond B.
Development of resistance to botulinum toxin type A in patients with torticollis.
Mov Disord.
1994;
9
213-217
- 3
Jankovic J, Schwartz K.
Response and immunoresistance to botulinum toxin injections.
Neurology.
1995;
45
1743-1746
- 4
Kessler K R, Skutta M, Benecke for the German Dystonia Study Group R.
Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety,
and antibody frequency.
J Neurol.
1999;
246
265-274
- 5
Wissel J, Heinen F, Schenkel A, Doll B, Ebersbach G, Müller J, Poewe W.
Botulinum toxin A in the management of spastic gait disorders in children and young
adults with cerebral palsy: A randomized, double-blind study of “high-dose” versus
“low-dose” treatment.
Neuropediatrics.
1999;
30
120-124
- 6
Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P.
Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency
and significance.
Neurology.
1993;
43
1715-1718
Jochen Herrmann
Abteilung Neuropädiatrie und Muskelerkrankungen
Universitäts-Kinderklinik Freiburg
Mathildenstraße 1
79106 Freiburg
Germany
eMail: herrmann@kkl200.ukl.uni-freiburg.de
